Nuvation Bio

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 51

Market Cap: $767.6M

Website

Introduction: Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was fou...

Clinical Trials

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Advanced Solid Tumor
Platinum-resistant Ovarian Cancer (PROC)
HER2-negative Breast Cancer

Interventions: Drug: NUV-1511

First Posted Date: 2024-03-28

Last Posted Date: 2024-06-13

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 466

Registration Number: NCT06334432

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Fred Hutchinson, Seattle, Washington, United States
🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States

and more 4 locations

Study the Effect of Omeprazole on AB-106 Pharmacokinetics

Phase 1

Completed

Conditions: Pharmacokinetic Study

Interventions: Drug: Multiple administration of omeprazole Single administration of AB-106

First Posted Date: 2022-11-08

Last Posted Date: 2024-11-21

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 24

Registration Number: NCT05609929

Locations: 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China

A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: AB-106, digoxin

First Posted Date: 2022-05-03

Last Posted Date: 2024-11-21

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 16

Registration Number: NCT05357911

Locations: 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China

A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: AB-106, Itraconazole
Drug: AB-106, Rifampicin

First Posted Date: 2022-05-03

Last Posted Date: 2024-11-21

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 56

Registration Number: NCT05357820

Locations: 🇨🇳
Xuanwu Hospital of Capital Medical University, Beijing, China

Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Phase 2

Active, not recruiting

Conditions: Glioma

Interventions: Drug: safusidenib

First Posted Date: 2022-03-31

Last Posted Date: 2024-11-18

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 95

Registration Number: NCT05303519

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 6 locations

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Cancer of Ovary
Prostatic Cancer
Castration Resistant Prostatic Neoplasms
Breast Tumor
Cancer of the Ovary
Prostate Cancer
Cancer of the Prostate
Triple-negative Breast Cancer
Cancer of Breast
Ovary Cancer

Interventions: Drug: NUV-868
Drug: Enzalutamide
Drug: Olaparib

First Posted Date: 2022-02-23

Last Posted Date: 2024-10-02

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 657

Registration Number: NCT05252390

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
St. Vincent-Frontier Cancer Center, Billings, Montana, United States
🇺🇸
Morristown Medical Center, Morristown, New Jersey, United States

and more 27 locations

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Phase 1

Withdrawn

Conditions: Cancer of Prostate
Prostate Cancer
Castration Resistant Prostatic Neoplasms
Prostatic Cancer
Cancer of the Prostate
Prostate Neoplasm
Castrate Resistant Prostate Cancer
Castration Resistant Prostatic Cancer

Interventions: Drug: NUV-422
Drug: Enzalutamide

First Posted Date: 2022-01-13

Last Posted Date: 2022-08-05

Lead Sponsor: Nuvation Bio Inc.

Registration Number: NCT05191017

Locations: 🇺🇸
Pennsylvania Cancer Specialists and Research Institute, Gettysburg, Pennsylvania, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸
NEXT Virginia, Fairfax, Virginia, United States

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Phase 1

Withdrawn

Conditions: Advanced Breast Cancer
Breast Tumor
Metastatic Breast Cancer
Breast Carcinoma
Cancer of the Breast
Breast Cancer
Malignant Tumor of Breast
Cancer of Breast

Interventions: Drug: NUV-422
Drug: Fulvestrant

First Posted Date: 2022-01-13

Last Posted Date: 2023-07-11

Lead Sponsor: Nuvation Bio Inc.

Registration Number: NCT05191004

Locations: 🇺🇸
Pennsylvania Cancer Specialists and Research Institute, Gettysburg, Pennsylvania, United States
🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸
Compassionate Cancer Care Research Inc., Fountain Valley, California, United States

and more 2 locations

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

Phase 2

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Taletrectinib

First Posted Date: 2021-06-09

Last Posted Date: 2024-11-21

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 224

Registration Number: NCT04919811

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
SCRI - Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
Renovatio Clinical, Dallas, Texas, United States

and more 70 locations

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Phase 1

Terminated

Conditions: Cancer of Breast
Prostatic Cancer
Castrate Resistant Prostate Cancer
Recurrent Glioblastoma
Glial Cell Tumors
Malignant Tumor of Breast
Glioma, Malignant
Glioma, Mixed
Prostate Cancer
Cancer of the Prostate

Interventions: Drug: NUV-422

First Posted Date: 2020-09-09

Last Posted Date: 2023-07-14

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 74

Registration Number: NCT04541225

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸
Texas Oncology P.A. Austin, Austin, Texas, United States

and more 9 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy